Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis.

Date publication

avril 2017

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr JOUZEAU Jean-Yves

Tous les auteurs :
Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28247573

Résumé

Crohn's disease (CD) and rheumatoid arthritis are chronic, progressive and disabling conditions that frequently lead to structural tissue damage. Based on strategies originally developed for rheumatoid arthritis, the treatment goal for CD has recently moved from exclusively controlling symptoms to both clinical remission and complete mucosal healing (deep remission), with the final aim of preventing bowel damage and disability.

Mots clés

Antibodies, Monoclonal, Humanized, therapeutic use, Arthritis, Rheumatoid, drug therapy, Crohn Disease, drug therapy, Disease Progression, Goals, Humans, Patient Care Planning, trends, Prospective Studies, Ustekinumab, therapeutic use

Référence

Aliment. Pharmacol. Ther.. 2017 Apr;45(8):1058-1072